Stryker should be bought at current levels or on pullbacks, says RBC Capital After Stryker's results beat expectations, RBC Capital continues to believe that the company is well-positioned to remain one of the fastest growing medtech companies in 2014. The firm identifies Stryker as one of its favorite ideas for 2014 and keeps an Outperform rating on the stock.
News For SYK From The Last 14 Days
Check below for free stories on SYK the last two weeks.
Stryker upcoming analyst day may be catalyst for shares, says Argus Argus believes Stryker is well positioned to post stronger sales and earnings in the second half of the year as new products launch and surgical volume rebounds. The firm thinks the company's analyst day on September 17 could be a catalyst for the shares and it maintains its Buy rating and $102 price target on the stock.